14,346 Shares in Abbott Laboratories (NYSE:ABT) Purchased by Fiducient Advisors LLC

Fiducient Advisors LLC purchased a new position in Abbott Laboratories (NYSE:ABT) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 14,346 shares of the healthcare product maker’s stock, valued at approximately $1,623,000.

A number of other institutional investors also recently bought and sold shares of ABT. Redwood Park Advisors LLC acquired a new position in Abbott Laboratories during the fourth quarter valued at $25,000. Noble Wealth Management PBC purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at about $26,000. NewSquare Capital LLC lifted its holdings in shares of Abbott Laboratories by 78.4% in the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker’s stock valued at $27,000 after buying an additional 105 shares during the period. WealthTrak Capital Management LLC purchased a new stake in shares of Abbott Laboratories in the fourth quarter worth about $28,000. Finally, Rialto Wealth Management LLC acquired a new position in Abbott Laboratories in the fourth quarter valued at approximately $29,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Bank of America upped their price objective on shares of Abbott Laboratories from $133.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, March 10th. Evercore ISI upped their price objective on shares of Abbott Laboratories to $136.00 and gave the stock a “buy” rating in a research report on Thursday, January 2nd. StockNews.com lowered shares of Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 12th. UBS Group upped their price target on shares of Abbott Laboratories from $146.00 to $148.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Finally, Barclays reiterated an “overweight” rating and issued a $158.00 price objective (up from $149.00) on shares of Abbott Laboratories in a report on Monday, January 27th. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $137.94.

Abbott Laboratories Stock Up 1.9 %

ABT opened at $126.84 on Friday. The stock has a market capitalization of $219.98 billion, a price-to-earnings ratio of 16.58, a price-to-earnings-growth ratio of 2.52 and a beta of 0.80. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $141.23. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. The business has a 50-day moving average of $130.75 and a two-hundred day moving average of $121.34.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The firm had revenue of $10.97 billion for the quarter, compared to analysts’ expectations of $11.03 billion. During the same period in the previous year, the company posted $1.19 earnings per share. Abbott Laboratories’s revenue was up 7.2% compared to the same quarter last year. On average, research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be paid a $0.59 dividend. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.86%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 30.85%.

Insider Buying and Selling

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $128.50, for a total value of $3,054,573.50. Following the transaction, the executive vice president now owns 125,697 shares in the company, valued at $16,152,064.50. The trade was a 15.90 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Lisa D. Earnhardt sold 91,167 shares of the firm’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $133.82, for a total value of $12,199,967.94. Following the sale, the executive vice president now owns 71,928 shares of the company’s stock, valued at $9,625,404.96. This represents a 55.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 116,449 shares of company stock valued at $15,463,316. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.